


AMENDMENTS TO THE CLAIMS

1. (currently amended) A compound of the structure:



or pharmaceutically acceptable salt, ester or salt of ester thereof;

wherein R_1 is hydrogen, aliphatic, heteroaliphatic, alicyclic or aryl;

R_2 and R_3 are each independently hydrogen, halogen, hydroxyl, protected hydroxyl, or an aliphatic, heteroaliphatic, alicyclic or aryl moiety; or

R_1 and R_2 , when taken together, ~~may~~ form a substituted or unsubstituted, saturated or unsaturated cyclic ring of 3 to 8 carbon atoms;

or R_1 and R_3 , when taken together, ~~may~~ form a substituted or unsubstituted, saturated or unsaturated cyclic ring of 3 to 8 carbon atoms;

R_4 is hydrogen or halogen;

R_5 is hydrogen or an oxygen protecting group;

R_6 is hydrogen, hydroxyl, or protected hydroxyl;

n is 0-2;

R_7 , for each occurrence, is independently hydrogen, hydroxyl, or protected hydroxyl;

R_8 is hydrogen, halogen, hydroxyl, protected hydroxyl, alkyloxy, or an aliphatic moiety optionally substituted with hydroxyl, protected hydroxyl, SR_{12} , or $NR_{12}R_{13}$;

R_9 is $NR_{12}R_{13}$;

wherein R_{12} and R_{13} are, independently for each occurrence, hydrogen, aliphatic, heteroaliphatic, alicyclic or aryl; or a protecting group, and each of R_{12} and R_{13} are optionally further substituted with one or more occurrences of hydroxyl, protected hydroxyl, alkyloxy, amino, protected amino, alkylamino, aminoalkyl, or halogen,
 ~~R_8 and R_9 may, when taken together, form a saturated or unsaturated cyclic ring containing 1 to 4 carbon atoms and 1 to 3 nitrogen or oxygen atoms and is optionally~~

~~substituted with hydroxyl, protected hydroxyl, alkyloxy, amino, protected amino, alkylamino, aminoalkyl, or halogen;~~

R₁₀ is hydrogen, hydroxyl, protected hydroxyl, amino, or protected amino;


R₁₁ is hydrogen, hydroxyl or protected hydroxyl;

X is absent or is O, NH, N-alkyl, CH₂ or S;

Y is CHR₁₇, O, C=O, CR₁₇ or NR₁₇; and Z is CHR₁₈, O, C=O, CR₁₈ or NR₁₈, wherein each occurrence of R₁₇ and R₁₈ is independently hydrogen or aliphatic, or R₁₇ and R₁₈ taken together is -O-, -CH₂- or -NR₁₉-, wherein R₁₉ is hydrogen or C₁₋₆alkyl, and Y and Z ~~are may be~~ connected by a single or double bond.

2. (canceled)

3. (currently amended) A compound of the structure:



or pharmaceutically acceptable salt, ester or salt of ester thereof;

wherein: R₁ is hydrogen, straight or branched C₁₋₆alkyl, straight or branched C₁₋₆heteroalkyl, or aryl,

wherein the alkyl, heteroalkyl, and aryl groups may optionally be substituted with one or more occurrences of halogen, hydroxyl or protected hydroxyl;

R₂ and R₃ are each independently hydrogen, halogen, hydroxyl, protected hydroxyl, straight or branched C₁₋₆alkyl, straight or branched C₁₋₆heteroalkyl, or aryl,

wherein the alkyl, heteroalkyl, and aryl groups may optionally be substituted with one or more occurrences of halogen, hydroxyl or protected hydroxyl; or

R₁ and R₂, when taken together, ~~may~~ form a saturated or unsaturated cyclic ring of 3 to 8 carbon atoms, optionally substituted with one or more occurrences of halogen; or

R₁ and R₃, when taken together, ~~may~~ form a saturated or unsaturated cyclic ring of 3 to 8 carbon atoms, optionally substituted with one or more occurrences of halogen;

R₄ is hydrogen or halogen;

R₅ is hydrogen or a protecting group;

R₆ is hydrogen, hydroxyl, or protected hydroxyl;

n is 0-2;

R₇, for each occurrence, is independently hydrogen, hydroxyl, or protected hydroxyl;

R₈ is hydrogen, halogen, hydroxyl, protected hydroxyl, alkyloxy, or C₁₋₆alkyl optionally substituted with hydroxyl, protected hydroxyl, SR₁₂, or NR₁₂R₁₃;

R₉ is NR₁₂R₁₃;

wherein R₁₂ and R₁₃ are, independently for each occurrence, hydrogen, C₁₋₆alkyl, aryl, alkylaryl, or a protecting group, and each of R₁₂ and R₁₃ are optionally further substituted with one or more occurrences of hydroxyl, protected hydroxyl, alkyloxy, amino, protected amino, alkylamino, aminoalkyl, or halogen,

~~R₈ and R₉ may, when taken together, form a saturated or unsaturated cyclic ring containing 1 to 4 carbon atoms and 1 to 3 nitrogen or oxygen atoms and is optionally substituted with hydroxyl, protected hydroxyl, alkyloxy, amino, protected amino, alkylamino, aminoalkyl, or halogen;~~


R₁₀ is hydrogen, hydroxyl, protected hydroxyl, amino, or protected amino;

R₁₁ is hydrogen, hydroxyl or protected hydroxyl;

X is absent or is O, NH, N-alkyl, CH₂ or S;


Y is CHR₁₇, O, C=O, CR₁₇ or NR₁₇; and Z is CHR₁₈, O, C=O, CR₁₈ or NR₁₈, wherein each occurrence of R₁₇ and R₁₈ is independently hydrogen or C₁₋₆alkyl, or R₁₇ and R₁₈ taken together is -O-, -CH₂- or -NR₁₉-, wherein R₁₉ is hydrogen or C₁₋₆alkyl, and Y and Z are may be connected by a single or double bond.

4. (original) The compound of claim 3, where X is oxygen and n is 1.
5. (original) The compound of claim 3, where R₄ is halogen.
6. (original) The compound of claim 3, where R₄ is fluorine.
7. (original) The compound of claim 3, where Y and Z together represent -CH=CH-
8. (original) The compound of claim 3, where Y and Z together represent trans -CH=CH-.
9. (currently amended) The compound of claim 3, wherein R₁ and R₂ are each methyl and R₃ is hydrogen and the compound is of ~~has~~ the structure:



wherein R_4 - R_{11} , n , X , Y and Z are as defined in claim 3.

10. (original) The compound of claim 9, wherein X is oxygen and n is 1.
11. (original) The compound of claim 9, wherein R_4 is halogen.
12. (original) The compound of claim 9, wherein Y and Z together represent $-\text{CH}=\text{CH}-$.
13. (original) The compound of claim 9, wherein X is oxygen, n is 1, R_4 is halogen and Y and Z together represent $-\text{CH}=\text{CH}-$.
14. (original) The compound of claim 12 or 13 wherein $-\text{CH}=\text{CH}-$ is trans.
15. (currently amended) The compound of claim 3, wherein R_9 is $\text{NR}_{12}\text{R}_{13}$ and the compound is of ~~has the~~ structure:




wherein R_1 - R_{12} , n , X , Y and Z are as defined in claim 3, or

R_{13} and R_8 ~~may~~, when taken together, form a cyclic ring containing 1 to 4 carbon atoms and 1 to 3 nitrogen or oxygen atoms and is optionally substituted with hydrogen, alkyloxy, amino, alkylamino, aminoalkyl, and halogen.

16. (original) The compound of claim 15, wherein X is oxygen and n is 1.
17. (original) The compound of claim 15, wherein R_4 is halogen.
18. (original) The compound of claim 15, wherein Y and Z together represent $-\text{CH}=\text{CH}-$.

19. (original) The compound of claim 15, wherein R_1 and R_2 are each methyl and R_3 is hydrogen.
20. (original) The compound of claim 15, wherein X is oxygen, n is 1, R_1 and R_2 are each methyl, R_3 is hydrogen, R_4 is halogen, and Y and Z together represent $-\text{CH}=\text{CH}-$.
21. (original) The compound of claim 18 or 20, wherein $-\text{CH}=\text{CH}-$ is trans.
22. (currently amended) The compound of claim 1, wherein the compound is of having the structure:



or pharmaceutically acceptable salt, ester or salt of ester thereof.

23-36. (canceled)

37. (previously presented) A pharmaceutical composition comprising:
a compound of any one of claims 1, 3, 9 and 15; or pharmaceutically acceptable salt,
ester or salt of ester thereof; and a pharmaceutically acceptable carrier.

38. (original) The pharmaceutical composition of claim 37, wherein the compound is present
in an amount effective to inhibit NF- κ B activation.

39-42. (canceled)


43. (original) The pharmaceutical composition of claim 37, wherein the compound is present
in an amount effective to have an anti-inflammatory effect.


44. (original) The pharmaceutical composition of claim 37, wherein the compound is present
in an amount effective to treat psoriasis.

45. (original) The pharmaceutical composition of claim 37, wherein the compound is present
in an amount effective to reduce skin photodamage.

46-65. (canceled)

66. (currently amended) The pharmaceutical composition of claim 37 wherein the compound
has the structure:





or pharmaceutically acceptable salt, ester or salt of ester thereof.

67-83. (canceled)

84. (withdrawn) A method for treating an inflammatory and/or autoimmune disorder or a disorder resulting from increased angiogenesis and/or cell proliferation comprising:
administering to a subject in need thereof a therapeutically effective amount of a compound of any one of claims 1, 3, 9 and 15; and a pharmaceutically acceptable carrier or diluent.

85. (withdrawn) The method of claim 84, wherein the method is for treating a disorder selected from the group consisting of rheumatoid arthritis, psoriasis, asthma, cancer, sepsis, inflammatory bowel disease, atopic dermatitis, Crohn's disease, and autoimmune disorders.


86. (withdrawn) The method of claim 84, wherein the method is for treating rheumatoid arthritis.

87. (withdrawn) The method of claim 84, wherein the method is for treating psoriasis.

88. (withdrawn) The method of claim 84, wherein the method is for treating asthma.

89-107. (canceled)


108. (withdrawn, currently amended) The method of claim 84, wherein the compound is of ~~has the~~ structure:



or pharmaceutically acceptable salt, ester or salt of ester thereof.

109-118. (canceled)

119. (withdrawn, currently amended) A method for providing protection against UVB-induced photodamage to a subject, said method comprising:
administering to the subject in need thereof a composition comprising a compound of the structure:



or pharmaceutically acceptable salt, ester or salt of ester thereof;

wherein R_1 is hydrogen, straight or branched C_{1-6} alkyl, straight or branched C_{1-6} heteroalkyl, or aryl,

wherein the alkyl, heteroalkyl, and aryl groups may optionally be substituted with one or more occurrences of halogen, hydroxyl or protected hydroxyl;

R_2 and R_3 are each independently hydrogen, halogen, hydroxyl, protected hydroxyl, straight or branched C_{1-6} alkyl, straight or branched C_{1-6} heteroalkyl, or aryl,

wherein the alkyl, heteroalkyl, and aryl groups may optionally be substituted with one or more occurrences of halogen, hydroxyl or protected hydroxyl; or

R_1 and R_2 , when taken together, may form a saturated or unsaturated cyclic ring of 3 to 8 carbon atoms, optionally substituted with one or more occurrences of halogen; or

R_1 and R_3 , when taken together, may form a saturated or unsaturated cyclic ring of 3 to 8 carbon atoms, optionally substituted with one or more occurrences of halogen;

R_4 is hydrogen or halogen;

R_5 is hydrogen or an oxygen protecting group;

R_6 is hydrogen, hydroxyl, or protected hydroxyl;

n is 0-2;

R_7 , for each occurrence, is independently hydrogen, hydroxyl, or protected hydroxyl;

R_8 is hydrogen, halogen, hydroxyl, protected hydroxyl, alkyloxy, or C_{1-6} alkyl optionally substituted with hydroxyl, protected hydroxyl, SR_{12} , or $NR_{12}R_{13}$;

R_9 is $NR_{12}R_{13}$;

wherein R_{12} and R_{13} are, independently for each occurrence, hydrogen, C_{1-6} alkyl, aryl, alkylaryl, or a protecting group, and each of R_{12} and R_{13} are optionally further substituted with one or more occurrences of hydroxyl, protected hydroxyl, alkyloxy, amino, protected amino, alkylamino, aminoalkyl, or halogen,

~~R₈ and R₉ may, when taken together, form a saturated or unsaturated cyclic ring containing 1 to 4 carbon atoms and 1 to 3 nitrogen or oxygen atoms and is optionally substituted with hydroxyl, protected hydroxyl, alkyloxy, amino, protected amino, alkylamino, aminoalkyl, or halogen;~~

R₁₀ is hydrogen, hydroxyl, protected hydroxyl, amino, or protected amino;


R₁₁ is hydrogen, hydroxyl or protected hydroxyl;

X is absent or is O, NH, N-alkyl, CH₂ or S;

Y is CHR₁₇, O, C=O, CR₁₇ or NR₁₇; and Z is CHR₁₈, O, C=O, CR₁₈ or NR₁₈, wherein each occurrence of R₁₇ and R₁₈ is independently hydrogen or C₁₋₆alkyl, or R₁₇ and R₁₈ taken together is -O-, -CH₂- or -NR₁₉-, wherein R₁₉ is hydrogen or C₁₋₆alkyl, and Y and Z are may be connected by a single or double bond; and

a pharmaceutically acceptable carrier or diluent.

120. (withdrawn) The method of claim 119, wherein in the step of administering, the composition is administered topically.
121. (withdrawn) The method of claim 119, wherein the photodamage is skin wrinkles.
122. (withdrawn) The method of claim 119, wherein the photodamage is a skin cancer.
123. (withdrawn, currently amended) A method for ~~preventing or~~ reducing the rate of restenosis, comprising:
inserting a stent into an obstructed blood vessel, the stent having a generally tubular structure, the surface of the structure being coated with (or otherwise adapted to release) a composition comprising a compound of the structure:



or pharmaceutically acceptable salt, ester or salt of ester thereof;

wherein R_1 is hydrogen, straight or branched C_{1-6} alkyl, straight or branched C_{1-6} heteroalkyl, or aryl,

wherein the alkyl, heteroalkyl, and aryl groups may optionally be substituted with one or more occurrences of halogen, hydroxyl or protected hydroxyl;

R_2 and R_3 are each independently hydrogen, halogen, hydroxyl, protected hydroxyl, straight or branched C_{1-6} alkyl, straight or branched C_{1-6} heteroalkyl, or aryl,

wherein the alkyl, heteroalkyl, and aryl groups may optionally be substituted with one or more occurrences of halogen, hydroxyl or protected hydroxyl; or

R_1 and R_2 , when taken together, ~~may~~ form a saturated or unsaturated cyclic ring of 3 to 8 carbon atoms, optionally substituted with one or more occurrences of halogen; or

R_1 and R_3 , when taken together, ~~may~~ form a saturated or unsaturated cyclic ring of 3 to 8 carbon atoms, optionally substituted with one or more occurrences of halogen;

R_4 is hydrogen or halogen;

R_5 is hydrogen or an oxygen protecting group;

R_6 is hydrogen, hydroxyl, or protected hydroxyl;

n is 0-2;

R_7 , for each occurrence, is independently hydrogen, hydroxyl, or protected hydroxyl;

R_8 is hydrogen, halogen, hydroxyl, protected hydroxyl, alkyloxy, or C_{1-6} alkyl optionally substituted with hydroxyl, protected hydroxyl, SR_{12} , or $NR_{12}R_{13}$;

R_9 is $NR_{12}R_{13}$;

wherein R_{12} and R_{13} are, independently for each occurrence, hydrogen, C_{1-6} alkyl, aryl, alkylaryl, or a protecting group, and each of R_{12} and R_{13} are optionally further substituted with one or more occurrences of hydroxyl, protected hydroxyl, alkyloxy, amino, protected amino, alkylamino, aminoalkyl, or halogen,

~~R_8 and R_9 may, when taken together, form a saturated or unsaturated cyclic ring containing 1 to 4 carbon atoms and 1 to 3 nitrogen or oxygen atoms and is optionally substituted with hydroxyl, protected hydroxyl, alkyloxy, amino, protected amino, alkylamino, aminoalkyl, or halogen;~~

R_{10} is hydrogen, hydroxyl, protected hydroxyl, amino, or protected amino;


R_{11} is hydrogen, hydroxyl or protected hydroxyl;

X is absent or is O, NH, N-alkyl, CH_2 or S;

Y is CHR_{17} , O, $\text{C}=\text{O}$, CR_{17} or NR_{17} ; and Z is CHR_{18} , O, $\text{C}=\text{O}$, CR_{18} or NR_{18} , wherein each occurrence of R_{17} and R_{18} is independently hydrogen or C_{1-6} alkyl, or R_{17} and R_{18} taken together is $-\text{O}-$, $-\text{CH}_2-$ or $-\text{NR}_{19}-$, wherein R_{19} is hydrogen or C_{1-6} alkyl, and Y and Z ~~are may be~~ connected by a single or double bond; and optionally a pharmaceutically acceptable carrier or diluent;

such that the obstruction is eliminated and the composition is delivered in amounts effective to prevent or reduce the rate of restenosis.

124. (withdrawn, currently amended) A method for expanding the lumen of a body passageway, comprising:
inserting a stent into the passageway, the stent having a generally tubular structure, the surface of the structure being coated with (or otherwise adapted to release) a composition comprising a compound of the structure:



or pharmaceutically acceptable salt, ester or salt of ester thereof;

wherein R_1 is hydrogen, straight or branched C_{1-6} alkyl, straight or branched C_{1-6} heteroalkyl, or aryl,

wherein the alkyl, heteroalkyl, and aryl groups may optionally be substituted with one or more occurrences of halogen, hydroxyl or protected hydroxyl;

R_2 and R_3 are each independently hydrogen, halogen, hydroxyl, protected hydroxyl, straight or branched C_{1-6} alkyl, straight or branched C_{1-6} heteroalkyl, or aryl,

wherein the alkyl, heteroalkyl, and aryl groups may optionally be substituted with one or more occurrences of halogen, hydroxyl or protected hydroxyl; or

R_1 and R_2 , when taken together, ~~may~~ form a saturated or unsaturated cyclic ring of 3 to 8 carbon atoms, optionally substituted with one or more occurrences of halogen; or

R_1 and R_3 , when taken together, ~~may~~ form a saturated or unsaturated cyclic ring of 3 to 8 carbon atoms, optionally substituted with one or more occurrences of halogen;

R₄ is hydrogen or halogen;

R₅ is hydrogen or a protecting group;

R₆ is hydrogen, hydroxyl, or protected hydroxyl;

n is 0-2;

R₇, for each occurrence, is independently hydrogen, hydroxyl, or protected hydroxyl;

R₈ is hydrogen, halogen, hydroxyl, protected hydroxyl, alkyloxy, or C₁₋₆alkyl optionally substituted with hydroxyl, protected hydroxyl, SR₁₂, or NR₁₂R₁₃;

R₉ is NR₁₂R₁₃;

wherein R₁₂ and R₁₃ are, independently for each occurrence, hydrogen, C₁₋₆alkyl, aryl, alkylaryl, or a protecting group, and each of R₁₂ and R₁₃ are optionally further substituted with one or more occurrences of hydroxyl, protected hydroxyl, alkyloxy, amino, protected amino, alkylamino, aminoalkyl, or halogen,

~~R₈ and R₉ may, when taken together, form a saturated or unsaturated cyclic ring containing 1 to 4 carbon atoms and 1 to 3 nitrogen or oxygen atoms and is optionally substituted with hydroxyl, protected hydroxyl, alkyloxy, amino, protected amino, alkylamino, aminoalkyl, or halogen;~~

R₁₀ is hydrogen, hydroxyl, protected hydroxyl, amino, or protected amino;


R₁₁ is hydrogen, hydroxyl or protected hydroxyl;

X is absent or is O, NH, N-alkyl, CH₂ or S;

Y is CHR₁₇, O, C=O, CR₁₇ or NR₁₇; and Z is CHR₁₈, O, C=O, CR₁₈ or NR₁₈, wherein each occurrence of R₁₇ and R₁₈ is independently hydrogen or C₁₋₆alkyl, or R₁₇ and R₁₈ taken together is -O-, -CH₂- or -NR₁₉-, wherein R₁₉ is hydrogen or C₁₋₆alkyl, and Y and Z are ~~may be~~ connected by a single or double bond; and optionally a pharmaceutically acceptable carrier or diluent;

such that the passageway is expanded.

125. (withdrawn) The method of claim 124, wherein the lumen of a body passageway is expanded in order to eliminate a biliary, gastrointestinal, esophageal, tracheal/bronchial, urethral and/or vascular obstruction.
126. (withdrawn) The method of claim 125, wherein the lumen of a body passageway is expanded in order to eliminate a vascular obstruction.
127. (currently amended) A compound of the structure:



or pharmaceutically acceptable salt, ester or salt of ester thereof;

wherein R_1 is hydrogen, straight or branched C_{1-6} alkyl, straight or branched C_{1-6} heteroalkyl, or aryl,

wherein the alkyl, heteroalkyl, and aryl groups may optionally be substituted with one or more occurrences of halogen, hydroxyl or protected hydroxyl;

R_2 and R_3 are each independently hydrogen, halogen, hydroxyl, protected hydroxyl, straight or branched C_{1-6} alkyl, straight or branched C_{1-6} heteroalkyl, or aryl,

wherein the alkyl, heteroalkyl, and aryl groups may optionally be substituted with one or more occurrences of halogen, hydroxyl or protected hydroxyl; or

R_1 and R_2 , when taken together, ~~may~~ form a saturated or unsaturated cyclic ring of 3 to 8 carbon atoms, optionally substituted with one or more occurrences of halogen; or

R_1 and R_3 , when taken together, ~~may~~ form a saturated or unsaturated cyclic ring of 3 to 8 carbon atoms, optionally substituted with one or more occurrences of halogen;

R_5 is hydrogen or a protecting group;

R_6 is hydrogen, hydroxyl, or protected hydroxyl;

n is 0-2;


R_7 , for each occurrence, is independently hydrogen, hydroxyl, or protected hydroxyl;

R_8 is hydrogen, halogen, hydroxyl, protected hydroxyl, alkyloxy, or C_{1-6} alkyl optionally substituted with hydroxyl, protected hydroxyl, SR_{12} , or $NR_{12}R_{13}$;

R_{12} and R_{13} are, independently for each occurrence, hydrogen, C_{1-6} alkyl, aryl, alkylaryl, or a protecting group, and each of R_{12} and R_{13} are optionally further substituted with one or more occurrences of hydroxyl, protected hydroxyl, alkyloxy, amino, protected amino, alkylamino, aminoalkyl, or halogen; and


R_{10} is hydrogen, hydroxyl, protected hydroxyl, amino, or protected amino.

128. (previously presented) A compound of claim 127, wherein R₁₂ is methyl, ethyl, propyl, isopropyl or butyl, optionally substituted with one or more occurrences of hydroxyl or protected hydroxyl and wherein R₁₃ is hydrogen or C₁₋₆alkyl.
129. (currently amended) A compound of the formula:




or a pharmaceutically acceptable salt, ester or salt of ester thereof[[]];

130. (new) A compound of claim 129, wherein the compound is of the formula:



131. (new) A compound of the formula:



or a pharmaceutically acceptable salt, ester or salt of ester thereof.

132. (new) A compound of claim 131, wherein the compound is of the formula:

